MA53186A1 - Anticorps monoclonal qui se lie spécifiquement à cd20 - Google Patents
Anticorps monoclonal qui se lie spécifiquement à cd20Info
- Publication number
- MA53186A1 MA53186A1 MA53186A MA53186A MA53186A1 MA 53186 A1 MA53186 A1 MA 53186A1 MA 53186 A MA53186 A MA 53186A MA 53186 A MA53186 A MA 53186A MA 53186 A1 MA53186 A1 MA 53186A1
- Authority
- MA
- Morocco
- Prior art keywords
- monoclonal antibody
- specifically binds
- relates
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne le domaine de la biotechnologie et porte sur un anticorps monoclonal qui se lie spécifiquement à cd20. L'invention concerne des adn qui codent pour ledit anticorps, qui correspondent aux vecteurs d'expression, et des procédés de production ainsi que des méthodes de traitement utilisant ces anticorps.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018138510A RU2724469C2 (ru) | 2018-10-31 | 2018-10-31 | Моноклональное антитело, которое специфически связывается с cd20 |
PCT/RU2019/050205 WO2020091634A1 (fr) | 2018-10-31 | 2019-10-30 | Anticorps monoclonal qui se lie spécifiquement à cd20 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53186A1 true MA53186A1 (fr) | 2022-02-28 |
MA53186B2 MA53186B2 (fr) | 2023-05-31 |
Family
ID=70462324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53186A MA53186B2 (fr) | 2018-10-31 | 2019-10-30 | Anticorps monoclonal qui se lie spécifiquement à cd20 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20220089761A1 (fr) |
EP (1) | EP3875486A4 (fr) |
JP (1) | JP2022506430A (fr) |
KR (1) | KR20210084604A (fr) |
CN (1) | CN113272329A (fr) |
AR (1) | AR116937A1 (fr) |
AU (1) | AU2019373999A1 (fr) |
BR (1) | BR112021008326A2 (fr) |
CA (1) | CA3117486A1 (fr) |
CL (1) | CL2021001104A1 (fr) |
CO (1) | CO2021005178A2 (fr) |
EA (1) | EA202191173A1 (fr) |
EC (1) | ECSP21028958A (fr) |
IL (1) | IL282742A (fr) |
JO (1) | JOP20210100A1 (fr) |
MA (1) | MA53186B2 (fr) |
MX (1) | MX2021005033A (fr) |
PE (1) | PE20211731A1 (fr) |
PH (1) | PH12021550991A1 (fr) |
RU (1) | RU2724469C2 (fr) |
SG (1) | SG11202104248UA (fr) |
TW (1) | TW202031682A (fr) |
UY (1) | UY38432A (fr) |
WO (1) | WO2020091634A1 (fr) |
ZA (1) | ZA202102874B (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024025440A1 (fr) * | 2022-07-26 | 2024-02-01 | Joint Stock Company "Biocad" | Composition pharmaceutique d'anticorps anti-cd20 et son utilisation |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (fr) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Proteine cd2 soluble a deux domaines |
KR920700674A (ko) | 1989-03-21 | 1992-08-10 | 원본미기재 | 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법 |
ES2112838T5 (es) | 1989-07-19 | 2004-09-01 | Connetics Corporation | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (fr) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
CA2476166C (fr) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation |
AU2011226858B2 (en) * | 2002-12-16 | 2015-01-22 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
US20040202658A1 (en) | 2003-04-09 | 2004-10-14 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
RU2489166C2 (ru) | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
WO2011100398A1 (fr) * | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Anticorps anti-cd20 et leurs utilisations |
CN102190728B (zh) * | 2010-03-17 | 2014-07-02 | 永卓博济(上海)生物医药技术有限公司 | 一种人源化抗cd20单克隆抗体 |
-
2018
- 2018-10-31 RU RU2018138510A patent/RU2724469C2/ru active
-
2019
- 2019-10-29 TW TW108139053A patent/TW202031682A/zh unknown
- 2019-10-30 EP EP19880700.0A patent/EP3875486A4/fr active Pending
- 2019-10-30 UY UY0001038432A patent/UY38432A/es unknown
- 2019-10-30 CA CA3117486A patent/CA3117486A1/fr active Pending
- 2019-10-30 JO JOP/2021/0100A patent/JOP20210100A1/ar unknown
- 2019-10-30 MA MA53186A patent/MA53186B2/fr unknown
- 2019-10-30 AU AU2019373999A patent/AU2019373999A1/en active Pending
- 2019-10-30 KR KR1020217016587A patent/KR20210084604A/ko active Search and Examination
- 2019-10-30 MX MX2021005033A patent/MX2021005033A/es unknown
- 2019-10-30 CN CN201980087511.2A patent/CN113272329A/zh active Pending
- 2019-10-30 JP JP2021523796A patent/JP2022506430A/ja active Pending
- 2019-10-30 SG SG11202104248UA patent/SG11202104248UA/en unknown
- 2019-10-30 EA EA202191173A patent/EA202191173A1/ru unknown
- 2019-10-30 PE PE2021000556A patent/PE20211731A1/es unknown
- 2019-10-30 US US17/288,234 patent/US20220089761A1/en active Pending
- 2019-10-30 WO PCT/RU2019/050205 patent/WO2020091634A1/fr unknown
- 2019-10-30 BR BR112021008326-0A patent/BR112021008326A2/pt unknown
- 2019-10-31 AR ARP190103167A patent/AR116937A1/es unknown
-
2021
- 2021-04-22 CO CONC2021/0005178A patent/CO2021005178A2/es unknown
- 2021-04-22 EC ECSENADI202128958A patent/ECSP21028958A/es unknown
- 2021-04-28 CL CL2021001104A patent/CL2021001104A1/es unknown
- 2021-04-28 IL IL282742A patent/IL282742A/en unknown
- 2021-04-29 ZA ZA2021/02874A patent/ZA202102874B/en unknown
- 2021-04-30 PH PH12021550991A patent/PH12021550991A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022506430A (ja) | 2022-01-17 |
WO2020091634A1 (fr) | 2020-05-07 |
MX2021005033A (es) | 2021-06-15 |
RU2018138510A (ru) | 2020-04-30 |
JOP20210100A1 (ar) | 2023-01-30 |
US20220089761A1 (en) | 2022-03-24 |
CO2021005178A2 (es) | 2021-04-30 |
UY38432A (es) | 2020-05-29 |
CN113272329A (zh) | 2021-08-17 |
IL282742A (en) | 2021-06-30 |
ZA202102874B (en) | 2022-06-29 |
AR116937A1 (es) | 2021-06-30 |
CA3117486A1 (fr) | 2020-05-07 |
PE20211731A1 (es) | 2021-09-06 |
RU2724469C2 (ru) | 2020-06-23 |
RU2018138510A3 (fr) | 2020-04-30 |
EA202191173A1 (ru) | 2021-07-28 |
PH12021550991A1 (en) | 2021-10-04 |
KR20210084604A (ko) | 2021-07-07 |
CL2021001104A1 (es) | 2021-12-03 |
MA53186B2 (fr) | 2023-05-31 |
EP3875486A1 (fr) | 2021-09-08 |
SG11202104248UA (en) | 2021-05-28 |
BR112021008326A2 (pt) | 2021-08-31 |
TW202031682A (zh) | 2020-09-01 |
ECSP21028958A (es) | 2021-05-31 |
EP3875486A4 (fr) | 2022-08-03 |
AU2019373999A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
MA46731A (fr) | Anticorps anti-tmprss2 et fragments de liaison à l'antigène | |
MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
MA49034B1 (fr) | Anticorps anti-lag3 | |
MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
EA202092847A1 (ru) | Антитела к cd3 и их применение | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
MA50259A1 (fr) | Stéroïdes et leurs conjugués-anticorps | |
MA35711B1 (fr) | Anticorps anti-alphabêtatcr | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
NI201900086A (es) | Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo. | |
MA39378A1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
CR20230469A (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
MA53186B2 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
CO2021008755A2 (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
EA202190954A1 (ru) | Гуманизированное моноклональное антитело против n-укороченного бета-амилоида | |
EA202092981A1 (ru) | Антитела к l1cam и их применение | |
EA202192173A1 (ru) | Анти-cd228 антитела и конъюгаты антитело-лекарственное средство |